Related Experiment Video
Updated: Feb 17, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
Severe piperacillin-tazobactam-induced hemolysis in a cystic fibrosis patient
Andrew D Kerkhoff1, Lauren Patrick2, Patricia Cornett1
1Department of Medicine University of California San Francisco School of Medicine San Francisco California.
Abstract:
Piperacillin-tazobactam is one of the most common causes of drug-induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life-threatening piperacillin-tazobactam-associated DIIHA in a 30-year-old woman with CF and propose management recommendations for piperacillin-tazobactam-associated DIIHA in CF patients.
Insights
Piperacillin-tazobactam frequently causes drug-induced immune hemolytic anemia (DIIHA), particularly in cystic fibrosis (CF) patients. This case highlights a severe DIIHA instance and offers management strategies for CF individuals.
Area of Science:
- Pharmacology
- Hematology
- Immunology
Background:
- Piperacillin-tazobactam is a widely used antibiotic, especially in cystic fibrosis (CF) patients.
- Drug-induced immune hemolytic anemia (DIIHA) is a known adverse effect of piperacillin-tazobactam.
- CF patients may have unique considerations regarding antibiotic-induced complications.
Observation:
- A 30-year-old female patient with CF developed life-threatening DIIHA.
- The DIIHA was directly associated with piperacillin-tazobactam administration.
- This case underscores the severity of DIIHA in this patient population.
Findings:
- Piperacillin-tazobactam can precipitate severe, life-threatening DIIHA.
- Early recognition and prompt management are critical for patient survival.
- Specific management protocols may be beneficial for CF patients experiencing DIIHA.
Implications:
- Healthcare providers should maintain a high index of suspicion for DIIHA in CF patients receiving piperacillin-tazobactam.
- Development of tailored management guidelines for piperacillin-tazobactam-associated DIIHA in CF patients is warranted.
- Further research into the mechanisms and prevention of DIIHA in this vulnerable population is needed.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Hypersensitivity Reactions: Cytolytic Reactions
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

